drugset / Trial / NCT01823133

Study for Investigate the Pharmacokinetic Drug Interactions Between Gemigliptin and Rosuvastatin

NCT01823133

Phase 1 Completed 30 enrolled LG Life Sciences
RandomizedCrossoverOpen-labelTreatment

Summary

Investigate the pharmacokinetic drug interactions between gemigliptin and rosuvastatin in healthy subjects

Timeline

Start
2013-04
Primary completion
2013-05
Completion
2013-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Gemigliptin Small molecule 50 mg
Subject Rosuvastatin Small molecule 20 mg

Indications

No indication recorded.